Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England

被引：76

作者：

Amin-Chowdhury, Zahin ^{[1
]}

Aiano, Felicity ^{[1
]}

Mensah, Anna ^{[1
]}

Sheppard, Carmen L. ^{[2
]}

Litt, David ^{[2
]}

Fry, Norman K. ^{[1
,2
]}

Andrews, Nick ^{[3
]}

Ramsay, Mary E. ^{[1
,4
]}

Ladhani, Shamez N. ^{[1
,5
]}

机构：

[1] Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England

[2] Publ Hlth England, Resp & Vaccine Preventable Bacterial Reference Un, London, England

[3] Publ Hlth England, Stat Modelling & Econ Dept, London, England

[4] London Sch Hyg & Trop Med, London, England

[5] St Georges Univ London, Paediat Infect Dis Res Grp PIDRG, London, England

来源：

CLINICAL INFECTIOUS DISEASES | 2021年 / 72卷 / 05期

关键词：

pneumococcal disease; bacterial coinfection; nosocomial infection; case fatality; risk factor; INFLUENZA; VACCINE; WALES; SEROTYPES; INCREASE;

D O I：

10.1093/cid/ciaa1728

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Streptococcus pneumoniae coinfection with influenza results in synergistic lethality, but there are limited data on pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods. Public Health England conducts invasive pneumococcal disease (IPD) and SARS-CoV-2 surveillance in England. IPD trends during 2000/2001-2019/2020 epidemiological years were analyzed and cases during February-June 2020 linked with laboratory-confirmed SARS-CoV-2 infections. Multivariable logistic regression was used to assess risk factors for death. Results. IPD incidence in 2019/2020 (7.6/100 000; n = 3964) was 30% (IRR, .70; 95% CI, .18-2.67) lower compared with 2018/2019 (10.9/100 000; n = 5666), with large reductions observed across all age groups during March-June 2020. There were 160 886 SARS-CoV-2 and 1137 IPD cases during February-June 2020, including 40 IPD/coronavirus disease 2019 (COVID-19) co-infections (.025% [95% CI, .018-.034] of SARS-CoV-2 infections; 3.5% [2.5-4.8] of IPD cases), 21 with COVID-19 diagnosed 3-27 days after IPD, and 27 who developed COVID-19 >28 days after IPD. Case-fatality rates (CFRs) were 62.5 (25/40), 47.6% (10/21), and 33.3% (9/27), respectively (P < .001). In addition to an independent association with increasing age and serotype group, CFR was 7.8-fold (95% CI, 3.8-15.8) higher in those with IPD/COVID-19 coinfection and 3.9-fold (95% CI, 1.4-10.7) higher in patients who developed COVID-19 3-27 days after IPD compared with patients with IPD only. Conclusions. Large declines in IPD were observed following COVID-19 lockdown. IPD/COVID-19 coinfections were rare but associated with high CFR, mainly in older adults. The rarity, age and serotype distribution of IPD/COVID-19 coinfections do not support wider extension of pneumococcal vaccination.

引用

页码：E65 / E75

页数：11

共 50 条

[1] Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency
Acter, Thamina
Uddin, Nizam
Das, Jagotamoy
Akhter, Afroza
Choudhury, Tasrina Rabia
Kim, Sunghwan
SCIENCE OF THE TOTAL ENVIRONMENT, 2020, 730
[2] Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic
Delsuz Rezaee
Somaye Bakhtiari
Farid Azizi Jalilian
Amin Doosti-Irani
Fatemeh Torkaman Asadi
Nastaran Ansari
Archives of Virology, 2023, 168
[3] Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic
Rezaee, Delsuz
Bakhtiari, Somaye
Jalilian, Farid Azizi
Doosti-Irani, Amin
Asadi, Fatemeh Torkaman
Ansari, Nastaran
ARCHIVES OF VIROLOGY, 2023, 168 (02)
[4] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid contamination of surfaces on a coronavirus disease 2019 (COVID-19) ward and intensive care unit
Redmond, Sarah N.
Dousa, Khalid M.
Jones, Lucas D.
Li, Daniel F.
Cadnum, Jennifer L.
Navas, Maria E.
Kachaluba, Nataliya M.
Silva, Sandra Y.
Zabarsky, Trina F.
Eckstein, Elizabeth C.
Procop, Gary W.
Donskey, Curtis J.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2021, 42 (02) : 215 - 217
[5] Effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus (COVID-19) vaccination on male fertility
Chen, Fei
Zhang, Yunfei
Zhang, Yingze
Li, Yuqi
Ma, Jiao
Qin, Yining
Deng, Shuwen
Zhang, Yuhan
Wang, Deyang
Wang, Haiying
Lin, Juan
SEXUAL HEALTH, 2024, 21 (02)
[6] The Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission from Patients With Undiagnosed Coronavirus Disease 2019 (COVID-19) to Roommates in a Large Academic Medical Center
Karan, Abraar
Klompas, Michael
Tucker, Robert
Baker, Meghan
Vaidya, Vineeta
Rhee, Chanu
CLINICAL INFECTIOUS DISEASES, 2022, 74 (06) : 1097 - 1100
[7] Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial
Boulware, David R.
Murray, Thomas A.
Proper, Jennifer L.
Tignanelli, Christopher J.
Buse, John B.
Liebovitz, David M.
Nicklas, Jacinda M.
Cohen, Kenneth
Puskarich, Michael A.
Belani, Hrishikesh K.
Siegel, Lianne K.
Klatt, Nichole R.
Odde, David J.
Karger, Amy B.
Ingraham, Nicholas E.
Hartman, Katrina M.
Rao, Via
Hagen, Aubrey A.
Patel, Barkha
Fenno, Sarah L.
Avula, Nandini
Reddy, Neha, V
Erickson, Spencer M.
Lindberg, Sarah
Fricton, Regina
Lee, Samuel
Zaman, Adnin
Saveraid, Hanna G.
Tordsen, Walker J.
Pullen, Matthew F.
Sherwood, Nancy E.
Huling, Jared D.
Bramante, Carolyn T.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1 - E9
[8] The Removal of Airborne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Microbial Bioaerosols by Air Filtration on Coronavirus Disease 2019 (COVID-19) Surge Units
Morris, Andrew Conway
Sharrocks, Katherine
Bousfield, Rachel
Kermack, Leanne
Maes, Mailis
Higginson, Ellen
Forrest, Sally
Pereira-Dias, Joana
Cormie, Claire
Old, Tim
Brooks, Sophie
Hamed, Islam
Koenig, Alicia
Turner, Andrew
White, Paul
Floto, R. Andres
Dougan, Gordon
Gkrania-Klotsas, Effrossyni
Gouliouris, Theodore
Baker, Stephen
Navapurkar, Vilas
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E97 - E101
[9] Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines
Epsi, Nusrat J.
Richard, Stephanie A.
Lindholm, David A.
Mende, Katrin
Ganesan, Anuradha
Huprikar, Nikhil
Lalani, Tahaniyat
Fries, Anthony C.
Maves, Ryan C.
Colombo, Rhonda E.
Larson, Derek T.
Smith, Alfred
Chi, Sharon W.
Maldonado, Carlos J.
Ewers, Evan C.
Jones, Milissa U.
Berjohn, Catherine M.
Libraty, Daniel H.
Edwards, Margaret Sanchez
English, Caroline
Rozman, Julia S.
Mody, Rupal M.
Colombo, Christopher J.
Samuels, Emily C.
Nwachukwu, Princess
Tso, Marana S.
Scher, Ann, I
Byrne, Celia
Rusiecki, Jennifer
Simons, Mark P.
Tribble, David
Broder, Christopher C.
Agan, Brian K.
Burgess, Timothy H.
Laing, Eric D.
Pollett, Simon D.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E439 - E449
[10] Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study
Danino, Dana
Ben-Shimol, Shalom
Van der Beek, Bart Adriaan
Givon-Lavi, Noga
Avni, Yonat Shemer
Greenberg, David
Weinberger, Daniel M.
Dagan, Ron
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E1154 - E1164

← 1 2 3 4 5 →